SecBot SecBot

CTSO drug pipeline

Cytosorbents Corp · 2 rated drugs
$4.16
−18.9% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.3%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhaseApproved / Commercialized
Time to marketAlready on the market (CE-marked in Europe, FDA-cleared in US)

CytoSorb hemoadsorption cartridge Updated Sep 5

What to watch

Watch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.

Bull case
  • CEO Phillip Chan and CFO Peter Mariani collectively purchased ~$149K of stock in open-market transactions in June 2026 at ~$0.40-0.44/share, signaling management conviction at a micro-cap with bearish analyst consensus
  • DrugSorb-ATR received FDA Breakthrough Device Designation (Nov 2025 and May 2026), which enables priority and interactive FDA review; a De Novo submission was made in Q1 2026
  • Cash burn has been reduced to ~$200K/month (ex-restructuring), extending runway toward operating cash flow breakeven
Bear case
  • Stock trades at ~$0.35, well below the $1.00 Nasdaq minimum bid price; must regain compliance by September 28, 2026 or face delisting, a reverse stock split would dilute and reduce liquidity
  • Q2 2026 revenue was flat YoY at $9.6M with a GAAP net loss of $0.07/share, missing consensus EPS of -$0.04 by 75%
  • Cash runway is limited at $5.9M, and the company is still loss-making
● neutral
Impact
PhasePreclinical / Development
Time to marketNot estimable from available sources. The device has not yet entered clinical trials; the most recent DoD contract (October 2022) was for customized filter design and integration into freeze-dried plasma collection systems.

HemoDefend-BGA Updated Nov 13

What to watch

HemoDefend-BGA is an early-stage, government-funded development project with no announced clinical trial start or regulatory submission timeline. Watch for any news of a first-in-human study or a new DoD contract milestone. The stock's primary near-term value drivers are the commercial CytoSorb product and the DrugSorb-ATR FDA de novo submission, not HemoDefend-BGA.

Bull case
  • The U.S. Department of Defense has awarded cumulative contracts of roughly $10M for HemoDefend-BGA development, signaling military interest in universal freeze-dried plasma for battlefield trauma care.
  • The technology leverages CytoSorbents' proprietary polymer adsorption platform, which is already commercialized in the CytoSorb product.
  • If successful, a freeze-dried universal plasma product could address a significant military and civilian medical need for a shelf-stable, blood-type-independent plasma product.
Bear case
  • HemoDefend-BGA remains in preclinical/development stage with no announced clinical trial start or regulatory submission timeline, years after the initial government contracts were awarded.
  • The program is a small part of CytoSorbents' pipeline; the company's primary focus and value drivers are the commercial CytoSorb product and the DrugSorb-ATR FDA de novo submission.
  • CytoSorbents has limited financial resources (Q3 2026 revenue of $9.7M, recent Nasdaq compliance challenges, and a market cap that required a reverse stock split in September 2026), which may constrain development timelines for early-stage programs.

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
May 13, 2026CytoSorbBreakthrough designation−7.5%−19.8%
Mar 31, 2026CytoSorbNDA filed−2.3%+10.7%
Nov 13, 2025CytoSorbBreakthrough designation+3.3%−2.7%